| Literature DB >> 33067541 |
Hao Chen1, Jing Tian1, Lan Guo1,2, Heng Du3,4,5.
Abstract
Dendritic spine injury underlies synaptic failure in many neurological disorders. Mounting evidence suggests a mitochondrial pathway of local nonapoptotic caspase signaling in mediating spine pruning. However, it remains unclear whether this caspase signaling plays a key role in spine loss when severe mitochondrial functional defects are present. The answer to this question is critical especially for some pathological states, in which mitochondrial deficits are prominent and difficult to fix. F1Fo ATP synthase is a pivotal mitochondrial enzyme and the dysfunction of this enzyme involves in diseases with spinopathy. Here, we inhibited F1Fo ATP synthase function in primary cultured hippocampal neurons by using non-lethal oligomycin A treatment. Oligomycin A induced mitochondrial defects including collapsed mitochondrial membrane potential, dissipated ATP production, and elevated reactive oxygen species (ROS) production. In addition, dendritic mitochondria underwent increased fragmentation and reduced positioning to dendritic spines along with increased caspase 3 cleavage in dendritic shaft and spines in response to oligomycin A. Concurring with these dendritic mitochondrial changes, oligomycin A-insulted neurons displayed spine loss and altered spine architecture. Such oligomycin A-mediated changes in dendritic spines were substantially prevented by the inhibition of caspase activation by using a pan-caspase inhibitor, quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone (Q-VD-OPh). Of note, the administration of Q-VD-OPh showed no protective effect on oligomycin A-induced mitochondrial dysfunction. Our findings suggest a pivotal role of caspase 3 signaling in mediating spine injury and the modulation of caspase 3 activation may benefit neurons from spine loss in diseases, at least, in those with F1Fo ATP synthase defects.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33067541 PMCID: PMC7568535 DOI: 10.1038/s41598-020-74613-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Oligomycin A treatment compromises mitochondrial function in cultured hippocampal neurons. (a) TMRM intensity indicated cultured hippocampal neuron dendritic (a1) and somatic (a2) mitochondrial membrane potential with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; *P < 0.05, ***P < 0.001. n = 5–10 cells or n = 15–20 dendritic segments per group, respectively. (a3) Representative live images of TMRM, images were recorded at time 0,5,10,15,20,25,30 min. Scale bar 50 µm. (b) Hippocampal neuronal ATP production with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; ***P < 0.001. n = 9 samples each group. (c) Mitosox Red intensity indicated cultured hippocampal neuron dendritic (c1) and soma (c2) Mitochondrial ROS level with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; ***P < 0.001. n = 12–15 cells or n = 20 dendritic segments per group, respectively. (c3) Representative images of Mitosox Red staining. Mitochondria are labeled with Mitotracker green. Hoechst was applied for nucleus staining. Scale bar 20 µm. (d) CM- H2DCFDA intensity indicted cultured hippocampal neuron dendritic (d1) and soma (d2) intra-neuronal ROS level with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; ***P < 0.001. n = 80–100 cells or n = 45 dendritic segments per group, respectively. (d3) Representative images of CM- H2DCFDA (green). Scale bar 50 µm.
Figure 2Oligomycin A treatment upregulates dendritic mitochondrial fragmentation and reduces spinal mitochondrial distribution in cultured hippocampal neuron. (a) Dendritic mitochondrial density of cultured hippocampal neurons with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; ***P < 0.001. n = 20 dendritic segments. (b1) Dendritic mitochondrial length of cultured hippocampal neurons with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; ***P < 0.001. n = 92 and 132 mitochondria, respectively. (b2) The corresponding cumulative curve of (b1). (c) The ratio of mitochondria-containing dendritic spines in cultured hippocampal neurons with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; *P < 0.05. n = 25–30 dendritic segments. (d) Representative images of dendritic spines (green) and mitochondria (red). Scale bar 5 µm.
Figure 3Oligomycin A treatment activates dendritic local apoptotic signaling in cultured hippocampal neurons. (a1) Dendritic mitochondria translocated Bax levels in cultured hippocampal neurons with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; ***P < 0.001. n = 9–12 dendritic segments. (a2) Representative images of mitochondria (red), Bax (blue) and dendrites (green). Scale bar 5 µm. (b1) Dendritic Cytochrome C release levels in cultured hippocampal neurons with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; ***P < 0.001. n = 21 dendritic segments. (b2) Representative images of mitochondria(red), Cytochrome C (blue) and dendrites (green). Scale bar 5 µm. (c1) Cleaved Caspase levels in cultured hippocampal neuron dendrite (c1) or dendritic spine (c2) with vehicle or 1 µM oligomycin A treatment. Unpaired student’s t-test; *P < 0.05. n = 10 dendritic segments. (c3) Representative images of Cleaved Caspase 3 (red) and dendrites (green). Scale bar 5 µm.
Figure 4Caspase 3 inhibition protects spine density and architecture in oligomycin A treated neurons. (a) Attenuated oligomycin A-induced dendritic protrusion reduction in 1 µM Q-VD-OPh treated hippocampal neurons. (a1) Dendritic protrusion of vehicle, 1 µM Q-VD-OPh and/or 1 µM oligomycin A treated hippocampal neurons. (a2–a5) Density of multiple types of spine in vehicle, 1 µM Q-VD-OPh and/or 1 µM oligomycin A treated hippocampal neurons (a2) Mushroom spine, (a3) Stubby spine, (a4) Filopodia, (a5) Thin spine. Two-way ANOVA followed by Bonferroni post hoc analysis; *P < 0.05, **P < 0.01 and ***P < 0.001. n = 10–15 dendritic segments. (a6) Representative images of dendritic protrusions (green). Scale bar 5 µm. (b1) Cleaved Caspase 3 expression levels in dendritic protrusions of vehicle, 1 µM Q-VD-OPh and/or 1 µM oligomycin A treated hippocampal neurons. Two-way ANOVA followed by Bonferroni post hoc analysis; *P < 0.05. n = 15–30 dendritic protrusions. (b2) Representative images of Cleaved Caspase 3 (red), dendritic protrusions (green) and MAP2 (blue). Scale bar 5 µm. (c) Mitochondrial membrane potential of vehicle, 1 µM Q-VD-OPh and/or 1 µM oligomycin A treated hippocampal neuron dendritic (c1) and somatic (c2) mitochondria in the indicated treated hippocampal neurons. Two-way ANOVA followed by Bonferroni post hoc analysis; *P < 0.05, NS not significant, n = 35–40 dendritic segments, respectively. (c3) Representative images of TMRM. Images were recorded at time 0, 5, 10, 15, 20, 25, 30 min. Scale bar 50 µm. (d) Hippocampal neuronal ATP production under vehicle, 1 µM Q-VD-OPh and/or 1 µM oligomycin A treated. Two-way ANOVA followed by Bonferroni post hoc analysis; NS, not significant, *P < 0.05. n = 6 samples. (e1) Hippocampal dendritic mitochondrial ROS levels of vehicle, 1 µM Q-VD-OPh and/or 1 µM oligomycin A treated neuron cultures. Two-way ANOVA followed by Bonferroni post hoc analysis; NS, not significant, ***P < 0.001, n = 20–30 dendritic segments. (e2) Representative images of Mitosox Red staining. Mitochondria are labeled with Mitotracker green. Hoechst was applied for nucleus staining. Scale bar 20 µm.